Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

App-based symptom tracking to optimize SARS-CoV-2 testing strategy using machine learning

View ORCID ProfileLeila F. Dantas, View ORCID ProfileIgor T. Peres, View ORCID ProfileLeonardo S. L. Bastos, View ORCID ProfileJanaina F. Marchesi, Guilherme F. G. de Souza, João Gabriel M. Gelli, View ORCID ProfileFernanda A. Baião, Paula Maçaira, View ORCID ProfileSilvio Hamacher, View ORCID ProfileFernando A. Bozza
doi: https://doi.org/10.1101/2020.09.01.20186049
Leila F. Dantas
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leila F. Dantas
Igor T. Peres
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Igor T. Peres
Leonardo S. L. Bastos
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leonardo S. L. Bastos
Janaina F. Marchesi
2Instituto Tecgraf, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Janaina F. Marchesi
Guilherme F. G. de Souza
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
João Gabriel M. Gelli
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernanda A. Baião
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernanda A. Baião
Paula Maçaira
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvio Hamacher
1Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvio Hamacher
Fernando A. Bozza
3National Institute of Infectious Diseases Evandro Chagas (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil
4D’Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernando A. Bozza
  • For correspondence: bozza.fernando{at}gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tests are scarce resources, especially in low and middle-income countries, and the optimization of testing programs during a pandemic is critical for the effectiveness of the disease control. Hence, we aim to use the combination of symptoms to build a regression model as a screening tool to identify people and areas with a higher risk of SARS-CoV-2 infection to be prioritized for testing.

Materials and Methods We applied machine learning techniques and provided a visualization of potential regions with high densities of COVID-19 as a risk map. We performed a retrospective analysis of individuals registered in “Dados do Bem”, an app-based symptom tracker in use in Brazil.

Results From April 28 to July 16, 2020, 337,435 individuals registered their symptoms through the app. Of these, 49,721 participants were tested for SARS-CoV-2 infection, being 5,888 (11.8%) positive. Among self-reported symptoms, loss of smell (OR[95%CI]: 4.6 [4.4 - 4.9]), fever (2.6 [2.5 - 2.8]), and shortness of breath (2.1 [1.6-2.7]) were associated with SARS-CoV-2 infection. Our final model obtained a competitive performance, with only 7% of false-negative users among the predicted as negatives (NPV = 0.93). From the 287,714 users still not tested, our model estimated that only 34.5% are potentially infected, thus reducing the need for extensive testing of all registered users. The model was incorporated by the “Dados do Bem” app aiming to prioritize users for testing. We developed an external validation in the state of Goias and found that of the 465 users selected, 52% tested positive.

Conclusions Our results showed that the combination of symptoms might predict SARS-Cov-2 infection and, therefore, can be used as a tool by decision-makers to refine testing and disease control strategies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We would like to thank all collaborators from Dados do Bem, which specified and developed the application, and supported data collection. This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (Grant numbers 169049/20175 to L.F.D., 306802/20155 and 403863/20163 to S.H., 310523/20168 to F.A.B., 144636/20190 to I.T.P.); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) Finance Code 001 (Grant number 88887.178844/201800 to L.S.L.B); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); and Pontificia Universidade Catolica do Rio de Janeiro (PUC-Rio).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study is retrospective and had no human interference. All data acquired were anonymized, and the "Dados do Bem" app follows the Brazilian General Data Protection Regulation (Lei Geral de Protecao de Dados - LGPD). All users provided informed consent of de-identified data-use to non-commercial research upon registration in the app. All answers were optional.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from "Dados do Bem" but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of "Dados do Bem".

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 03, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
App-based symptom tracking to optimize SARS-CoV-2 testing strategy using machine learning
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
App-based symptom tracking to optimize SARS-CoV-2 testing strategy using machine learning
Leila F. Dantas, Igor T. Peres, Leonardo S. L. Bastos, Janaina F. Marchesi, Guilherme F. G. de Souza, João Gabriel M. Gelli, Fernanda A. Baião, Paula Maçaira, Silvio Hamacher, Fernando A. Bozza
medRxiv 2020.09.01.20186049; doi: https://doi.org/10.1101/2020.09.01.20186049
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
App-based symptom tracking to optimize SARS-CoV-2 testing strategy using machine learning
Leila F. Dantas, Igor T. Peres, Leonardo S. L. Bastos, Janaina F. Marchesi, Guilherme F. G. de Souza, João Gabriel M. Gelli, Fernanda A. Baião, Paula Maçaira, Silvio Hamacher, Fernando A. Bozza
medRxiv 2020.09.01.20186049; doi: https://doi.org/10.1101/2020.09.01.20186049

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)